Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[ b]thiophene 1,1-dioxide sulfonamides

Abstract

A series of selected benzo[ b]thiophene-5- and 6-sulfonamide derivatives previously reported to show cytotoxic activity and some others newly synthesized has been tested for the interactions with several CA isozymes, some of which are known to be involved in tumorigenesis (hCA IX), whereas others are ubiquitously found in many normal tissues (the cytosolic isoforms hCA I and II). The unsubstituted sulfonamides inhibited hCA I with inhibition constants in the range of 63–138 nM, hCA II with inhibition constants in the range of 6.3–8.8 nM, and hCA IX with inhibition constants in the range of 2.8–15 nM, being thus more active than clinically used inhibitors such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide or indisulam (E 7070). Some of these derivatives also showed some selectivity for the inhibition of the tumor-associated (hCA IX) over the cytosolic isozyme hCA II. Although these derivatives may act on many targets other than the CAs (such as the NADH oxidase) or may induce apoptosis by accumulation of reactive oxygen species, it is quite important to try to decipher as many as possible of the potential mechanisms that lead to derivatives with potent antitumor activity in order to develop novel therapeutic strategies for the management of cancer.